Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients?

Area of Science:

• Nephrology
• Cardiology
• Oxidative Stress Research

Background:

• Cardiovascular disease (CV) is the primary cause of mortality in end-stage renal disease (ESRD) patients.
• Oxidative stress, an imbalance between pro-oxidants and antioxidants, increases with chronic kidney disease progression and renal replacement therapy.
• Oxidative stress is linked to accelerated atherosclerosis, endothelial dysfunction, and increased CV mortality.

Purpose of the Study:

• To review existing data on antioxidant therapies for cardiovascular protection in ESRD patients.
• To explore the role of oxidative stress in the pathogenesis of cardiovascular complications in chronic kidney disease.

Main Methods:

• Literature review of studies investigating antioxidant administration for CV protection.
• Analysis of data on antioxidants such as vitamins E and C, statins, omega-3 fatty acids, and N-acetylcysteine.

Main Results:

• Oxidative stress and lipid peroxidation are implicated in endothelial dysfunction and atherogenesis in ESRD.
• Antioxidants are proposed to counteract free radical damage and ameliorate cardiovascular disease.
• Data from studies testing specific antioxidants for CV protection are summarized.

Conclusions:

• Oxidative stress plays a significant role in cardiovascular mortality in ESRD.
• Further research into antioxidant therapies may offer strategies to mitigate cardiovascular risk in these patients.